Segall Bryant & Hamill LLC Cuts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Segall Bryant & Hamill LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 4.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 70,286 shares of the company’s stock after selling 3,242 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Zoetis were worth $11,452,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ZTS. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Atlantic Edge Private Wealth Management LLC increased its stake in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the last quarter. Rakuten Securities Inc. lifted its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after buying an additional 166 shares in the last quarter. Quarry LP boosted its stake in shares of Zoetis by 45.9% in the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after buying an additional 96 shares during the last quarter. Finally, Asset Planning Inc bought a new position in shares of Zoetis in the fourth quarter valued at approximately $58,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 1.2 %

ZTS opened at $161.29 on Wednesday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company has a market cap of $72.22 billion, a PE ratio of 29.49, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a 50 day moving average of $166.64 and a 200 day moving average of $175.02.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.24%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Wall Street Analyst Weigh In

ZTS has been the topic of several research analyst reports. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus dropped their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $215.90.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.